Abstract： Objective： To observe the clinical effect of the therapy of Zhushui Tongyang Jiufei Prescription combined with induction chemotherapy on stage Ⅲb/Ⅳ non- small cell lung cancer(NSCLC). Methods： A total of 118 patients with stage Ⅲb/Ⅳ NSCLC were divided into the control group and the observation group according to the random number table method，with 59 cases in each group. The control group was treated with induction chemotherapy，and the observation group was additionally treated with Zhushui Tongyang Jiufei Prescription based on induction chemotherapy. The curative effects in the two groups were evaluated after three courses of treatment. The clinical effects were compared between the two groups. Before and after treatment， the changes of indexes of immune function and scores of Karnofsky Performance Score(KPS) were compared between the two groups. During treatment， the administration safety， including gastrointestinal reaction， decrease of white blood cell(WBC)， blood platelet count(BPC)， hemoglobin(Hb) and increase of alanine aminotransferase(ALT)， in the two groups was observed. Results：The total clinical effective rate was 27.12% in the observation group and 20.34% in the control group，the difference being no significance(P＞0.05). After treatment，the levels of CD8+ in the two groups were decreased when compared with those before treatment，and the levels of CD3+，CD4+ and CD4 +/CD8 + were increased(P＜0.05)； the level of CD8 + in the observation group was lower and the levels of CD3+、CD4+、CD4+/CD8+ in the observation group were higher than those in the control group(P＜ 0.05). During treatment，the incidence of gastrointestinal reaction and decrease of WBS，BPC and Hb and adverse reactions in the observation group were lower than those in the control group(P＜0.05)，and there was no significance being found in the comparison of incidence of increase of ALT between the two groups (P＞0.05). After treatment，the scores of KPS in the two groups were increased when compared with those before treatment(P＜0.05)，and the above score in the observation group was higher than that in the control group(P＜0.05). Conclusion：The therapy of Zhushui Tongyang Jiufei Prescription combined with induction chemotherapy for stage Ⅲb/Ⅳ NSCLC can relieve the decrease of immune function caused by induction chemotherapy，reduce the adverse reactions，and enhance the quality of life of patients.